-
2
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
4
-
-
0019408691
-
Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group
-
Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981; 48:899-903.
-
(1981)
Cancer
, vol.48
, pp. 899-903
-
-
Thigpen, T.1
Shingleton, H.2
Homesley, H.3
-
5
-
-
0021793908
-
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A gynecologic oncology group study
-
Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3:1079-1085.
-
J Clin Oncol
, vol.3
, pp. 1079-1085
-
-
Bonomi, P.1
Blessing, J.A.2
Stehman, F.B.3
-
6
-
-
0024747607
-
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A gynecologic onology group study
-
McGuire WP 3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7:1462-1468.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1462-1468
-
-
McGuire III, W.P.1
Arseneau, J.2
Blessing, J.A.3
-
7
-
-
0037486920
-
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Fracasso PM, Blessing JA, Wolf J, et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2003; 90:177-180.
-
(2003)
Gynecol Oncol
, vol.90
, pp. 177-180
-
-
Fracasso, P.M.1
Blessing, J.A.2
Wolf, J.3
-
8
-
-
0029041394
-
Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: A gynecologic oncology group study
-
Thigpen T, Blessing JA, Gallup DG, et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995; 57:376-379.
-
(1995)
Gynecol Oncol
, vol.57
, pp. 376-379
-
-
Thigpen, T.1
Blessing, J.A.2
Gallup, D.G.3
-
9
-
-
0024450677
-
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix
-
A Gynecologic Oncology Group study
-
Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1989; 7:341-343.
-
(1989)
Invest New Drugs
, vol.7
, pp. 341-343
-
-
Sutton, G.P.1
Blessing, J.A.2
Adcock, L.3
-
10
-
-
0032168956
-
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A gynecologic oncology group study
-
Look KY, Blessing JA, Levenback C, et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998; 70:334-338.
-
(1998)
Gynecol Oncol
, vol.70
, pp. 334-338
-
-
Look, K.Y.1
Blessing, J.A.2
Levenback, C.3
-
11
-
-
0033959650
-
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the gynecologic oncology group
-
Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol 2000; 76:204-207.
-
(2000)
Gynecol Oncol
, vol.76
, pp. 204-207
-
-
Schilder, R.J.1
Blessing, J.A.2
Morgan, M.3
-
12
-
-
0034089496
-
Topotecan in squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group
-
Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77:446-449.
-
(2000)
Gynecol Oncol
, vol.77
, pp. 446-449
-
-
Bookman, M.A.1
Blessing, J.A.2
Hanjani, P.3
-
13
-
-
0035281646
-
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A gynecologic oncology group study
-
Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19:1275-1278.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1275-1278
-
-
Curtin, J.P.1
Blessing, J.A.2
Webster, K.D.3
-
14
-
-
0029865737
-
Paclitaxel has moderate activity in squamous cervix cancer. A gynecologic oncology group study
-
McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792-795.
-
(1996)
J Clin Oncol
, vol.14
, pp. 792-795
-
-
McGuire, W.P.1
Blessing, J.A.2
Moore, D.3
-
15
-
-
34548437625
-
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007; 30:428-431.
-
(2007)
Am J Clin Oncol
, vol.30
, pp. 428-431
-
-
Garcia, A.A.1
Blessing, J.A.2
Vaccarello, L.3
Roman, L.D.4
-
16
-
-
10044278053
-
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: A gynecologic oncology group study
-
Muggia FM., Blessing JA., Waggoner S., et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol. 2005, 96, 108-111.
-
(2005)
Gynecol Oncol
, vol.96
, pp. 108-111
-
-
Muggia, F.M.1
Blessing, J.A.2
Waggoner, S.3
-
17
-
-
28044461278
-
Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer
-
Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005; 7:419-434.
-
(2005)
Curr Oncol Rep
, vol.7
, pp. 419-434
-
-
Tewari, K.S.1
Monk, B.J.2
-
18
-
-
0031023552
-
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A gynecologic oncology group study
-
Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15:165-171.
-
(1997)
J Clin Oncol
, vol.15
, pp. 165-171
-
-
Omura, G.A.1
Blessing, J.A.2
Vaccarello, L.3
-
19
-
-
0036534291
-
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study
-
Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002; 20:1832-1837.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1832-1837
-
-
Bloss, J.D.1
Blessing, J.A.2
Behrens, B.C.3
-
20
-
-
4143135504
-
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004; 22:3113-3119.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3113-3119
-
-
Moore, D.H.1
Blessing, J.A.2
McQuellon, R.P.3
-
21
-
-
23044495279
-
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A gynecologic oncology group study
-
Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23:4626-4633.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4626-4633
-
-
Long III, H.J.1
Bundy, B.N.2
Grendys Jr., E.C.3
-
22
-
-
0035025316
-
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study
-
Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81:213-215.
-
(2001)
Gynecol Oncol
, vol.81
, pp. 213-215
-
-
Muderspach, L.I.1
Blessing, J.A.2
Levenback, C.3
Moore Jr., J.L.4
-
23
-
-
0030953995
-
A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix
-
Papadimitriou CA, Dimopoulos MA, Giannakoulis N, et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997; 79:2391-2395.
-
(1997)
Cancer
, vol.79
, pp. 2391-2395
-
-
Papadimitriou, C.A.1
Dimopoulos, M.A.2
Giannakoulis, N.3
-
24
-
-
23044471142
-
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A gynecologic oncology group study
-
Monk BJ, Huang HQ, Cella D, Long HJ 3rd. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23:4617-4625.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4617-4625
-
-
Monk, B.J.1
Huang, H.Q.2
Cella, D.3
Long III, H.J.4
-
25
-
-
70350433286
-
Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A gynecologic oncology group study
-
Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4649-4655.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4649-4655
-
-
Monk, B.J.1
Sill, M.W.2
McMeekin, D.S.3
-
26
-
-
78149359590
-
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A gynecologic oncology group study
-
Cella D, Huang HQ, Monk BJ, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 119:531-537.
-
(2010)
Gynecol Oncol
, vol.119
, pp. 531-537
-
-
Cella, D.1
Huang, H.Q.2
Monk, B.J.3
-
27
-
-
74949119951
-
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer
-
Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)
-
Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010; 40:90-93.
-
(2010)
Jpn J Clin Oncol
, vol.40
, pp. 90-93
-
-
Saito, I.1
Kitagawa, R.2
Fukuda, H.3
-
28
-
-
70749125099
-
Prognostic factors for response to cisplatinbased chemotherapy in advanced cervical carcinoma: A gynecologic oncology group study
-
Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatinbased chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010; 116:44-49.
-
(2010)
Gynecol Oncol
, vol.116
, pp. 44-49
-
-
Moore, D.H.1
Tian, C.2
Monk, B.J.3
-
29
-
-
62949142263
-
Recent achievements and future developments in advanced and recurrent cervical cancer: Trials of the gynecologic oncology group
-
Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009; 36:170-180.
-
(2009)
Semin Oncol
, vol.36
, pp. 170-180
-
-
Tewari, K.S.1
Monk, B.J.2
-
30
-
-
0033561333
-
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
-
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144-1153.
-
(1999)
N Engl J Med
, vol.340
, pp. 1144-1153
-
-
Rose, P.G.1
Bundy, B.N.2
Watkins, E.B.3
-
31
-
-
77749237017
-
The rationale for the use of nonplatinum chemotherapy doublets for metastatic and recurrent cervical carcinoma
-
Tewari KS, Monk BJ. The rationale for the use of nonplatinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010; 8:108-115.
-
(2010)
Clin Adv Hematol Oncol
, vol.8
, pp. 108-115
-
-
Tewari, K.S.1
Monk, B.J.2
-
32
-
-
70350786938
-
Beyond platinum for metastatic and recurrent carcinoma of the cervix
-
Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie 2009; 32:552-554.
-
(2009)
Onkologie
, vol.32
, pp. 552-554
-
-
Tewari, K.S.1
Monk, B.J.2
-
33
-
-
80052604393
-
SCOTCERV: A phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer
-
Symonds RP, Davidson SE, Chan S, et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecol Oncol 2011; 123:105-109.
-
(2011)
Gynecol Oncol
, vol.123
, pp. 105-109
-
-
Symonds, R.P.1
Davidson, S.E.2
Chan, S.3
-
34
-
-
0034884282
-
Synergistic interaction between topotecan and microtubule-interfering agents
-
Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 2001; 48:188-196.
-
(2001)
Cancer Chemother Pharmacol
, vol.48
, pp. 188-196
-
-
Bahadori, H.R.1
Green, M.R.2
Catapano, C.V.3
-
35
-
-
4344663407
-
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: A phase I/II study
-
Stathopoulos GP, Rigatos SK, Christodoulou C, et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 2004; 54:259-264.
-
(2004)
Cancer Chemother Pharmacol
, vol.54
, pp. 259-264
-
-
Stathopoulos, G.P.1
Rigatos, S.K.2
Christodoulou, C.3
-
36
-
-
0842288949
-
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma
-
Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004; 92:635-638.
-
(2004)
Gynecol Oncol
, vol.92
, pp. 635-638
-
-
Tiersten, A.D.1
Selleck, M.J.2
Hershman, D.L.3
-
37
-
-
0037285662
-
Phase i study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
-
West W, Birch R, Schnell F, et al. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncologist 2003; 8:76-82.
-
(2003)
Oncologist
, vol.8
, pp. 76-82
-
-
West, W.1
Birch, R.2
Schnell, F.3
-
38
-
-
84894207820
-
Improved survival with bevacizumab in advanced cervical cancer
-
Tewari KS, Sill MW,Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734-743.
-
(2014)
N Engl J Med
, vol.370
, pp. 734-743
-
-
Tewari, K.S.1
Sill Mwlong III, H.J.2
-
39
-
-
84906819213
-
A limited access phase II trial of pemetrexed in combination with cisplatin in the treatment of advanced, persistent, or recurrent carcioma of the cervix
-
in press
-
Miller DS, Blessing JA, Ramondetta LM, et al. A limited access phase II trial of pemetrexed in combination with cisplatin in the treatment of advanced, persistent, or recurrent carcioma of the cervix. J Clin Oncol 2014. (in press).
-
(2014)
J Clin Oncol
-
-
Miller, D.S.1
Blessing, J.A.2
Ramondetta, L.M.3
|